Re: Effect of Androgen Deprivation Therapy on Other-Cause of Mortality in Elderly Patients with Clinically Localized Prostate Cancer Treated with Modern Radiotherapy: Is There a Negative Impact?
| Autor: | Tadayuki Kotsuma, Ken Yoshida, Kazuhiko Ogawa, Yasuo Yoshioka, Gen Suzuki, Kei Yamada, Takumi Shiraishi, Koji Masui, Satoaki Nakamura, Hideya Yamazaki, Tatsuyuki Nishikawa, Keisuke Otani, Norihiro Aibe, Koji Okihara, Daisuke Shimizu, Haruumi Okabe, Eiichi Tanaka |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty Urology medicine.medical_treatment Brachytherapy brachytherapy 030232 urology & nephrology MEDLINE lcsh:Medicine androgen deprivation therapy elderly Article Androgen deprivation therapy 03 medical and health sciences Prostate cancer 0302 clinical medicine Statistical significance Internal medicine Overall survival medicine In patient Survival rate business.industry lcsh:R General Medicine prostate cancer medicine.disease Radiation therapy IG-IMRT OCM 030220 oncology & carcinogenesis business |
| Zdroj: | Journal of Clinical Medicine, Vol 8, Iss 3, p 338 (2019) Journal of Clinical Medicine Volume 8 Issue 3 |
| ISSN: | 1527-3792 0022-5347 |
| DOI: | 10.1097/01.ju.0000614712.12731.f6 |
| Popis: | The influence of androgen deprivation therapy (ADT) on other-cause of mortality (OCM) was investigated in patients with localized prostate cancer treated with modern high-dose radiotherapy. A retrospective review was conducted on 1125 patients with localized prostate cancer treated with high-dose radiotherapy, including image-guided, intensity-modulated radiotherapy or brachytherapy with a median follow-up of 80.7 months. Overall survival rate was no different between ADT (+) and ADT (&minus ) group in high-, intermediate-, and low-risk groups. OCM was found in 71 patients, consisting of 4% (10/258) in the ADT (&minus ) group and 7% (61/858) in the ADT (+) group (p = 0.0422). The 10-year OCM-free survival rate (OCMFS), if divided by the duration of ADT (ADT naï ve (ADT (&minus )), ADT < 2-year, and ADT &ge 2-year groups), showed statistical significance, and was 90.7%, 88.2%, and 78.6% (p = 0.0039) for the ADT (&minus ), ADT < 2-year groups, respectively. In patients aged &ge 75 years, 10-year OCMFS for ADT (&minus 2-, and ADT &ge 2-year groups was 93.5% (at 115.6 months), 85.6%, and 60.7% (p = 0.0189), respectively, whereas it was 90.7%, 89.9%, and 89.0% (p = 0.4716), respectively, in their younger counterparts. In localized prostate cancer patients, treatment with longer ADT for &ge 2 years potentially increases the risk of OCM, especially in patients aged &ge 75 years. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|